SAN FRANCISCO (AP) — Eli Lilly’s Alzheimer’s treatment failed in a large clinical study, ending hope that researchers had finally found a drug that can slow the fatal, mind-robbing disease.
The drug company’s shares plunged 13 percent before the opening bell Wednesday.READ MORE: Summer Departs With Sweltering Temperatures; Smoky Skies Draped Over East Bay
The drug, solanezumab, missed the study’s main goal of significantly slowing cognitive decline in patients compared to a placebo or fake drug.
Eli Lilly and Co. had been studying the drug in patients with mild cases of the disease.READ MORE: Monterey Police Arrest Two For Numerous Offenses Following Shooting
Current Alzheimer’s treatments like Aricept and Namenda only temporarily ease symptoms such as memory loss, confusion and agitation. They don’t slow, stop or reverse the mental decline that happens when the brain’s nerve cells stop functioning normally.
At least 18 other drugs are in late-stage testing, including several similar to solanezumab.MORE NEWS: Scaled-Down Dreamforce Marks Major Step In San Francisco's COVID Economic Rebound
© Copyright 2016 The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten or redistributed.